Hypertension and cardiovascular risk

Hipertensión arterial y riesgo cardiovascular

Introduction: hypertension is one of the leading medical conditions worldwide and is an important cause of morbidity and mortality in low and middle-income countries. Objective: to determine the epidemiological importance of hypertension as a risk factor for cardiovascular diseases (CVD) in different studies carried out in the world, Latin America and Colombia. Methodology: a search of the scientific literature using the PudMed / Medline, Scielo, LILACS databases, as well as the medical journals and texts published by the Colombian Ministry of Health and Social Protection. Discussion and conclusions: more than 90% of hypertensive patients have primary hypertension, which is associated with increased peripheral vascular resistance. Prevalence and adequate management of hypertension are related with the socioeconomic characteristics of countries and individual educational level The increase in prevalence of chronic diseases together with important historical events, were determinant for the development of worldwide epidemiology studies such as the Framingham Heart Study. Diverse studies aimed to gather information on hypertension showing alarming figures in terms of awareness, treatment and control of this condition, have been conducted in Latin America and Colombia. Thus, identifying a need for programs for detecting hypertension, in order to design strategies to enable significant reduction of CVD. 

1. Hall J, Guyton A. Guyton y Hall. Distensibilidad vascular y funciones de los sistemas arterial y venoso En: Hall J., Editor. Tratado de fisiología médica. 13ed. Elsevier; 2016. p.169-178.
2. Boron W, Boulpaep E. Regulación de la presión arterial y del gasto cardíaco. En: Boulpaep E., Editor. Fisiología médica. 3ed. Elsevier; 2017. p.410-456.
3. Organización Mundial de la Salud. Hipertensión Arterial [Internet]. OMS; 2015 [citado 10 enero 2021]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hypertension
4. Organización Mundial de la Salud. Hipertensión [Internet]. Organización Mundial de la Salud; 2020 [citado 09 de enero de 2021]. Disponible en: https://www.who.int/topics/hypertension/es/
5. Whelton PK, Carey RM, Aronow WS, et al. 2017 CC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13‐e115. doi: 10.1161/HYP.0000000000000065
6. Williams B, Mancia G, Spiering W, Agabiti E, Azizi M, Burnier M, et al. Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial. Rev Esp Cardiol. 2019;72(2):160.e1-e78. doi: 10.1016/j.recesp.2018.12.005
7. Ronald GV. Hipertensión sistémica: mecanismos y diagnóstico. En: Bonow R, Braunwald E, Libby P, Mann D, Tomaselli G, Zipes D., Editor. Braunwald. Tratado de cardiología. 11ed. Elsevier; 2019. p.910-927.
8. Ministerio de Salud y Protección Social. Plan Decenal de Salud Pública PDSP, 2012-2021. Bogotá; 2012.
9. Nicolaou KC, Rigol S. A brief history of antibiotics and select advances in their synthesis. J Antibiot (Tokyo). 2018;71(2):153-184. doi: 10.1038/ja.2017.62
10. Mahmood S, Levy D, Vasan R y Wang T. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2014;383(9921):999–1008. doi: 10.1016/S0140-6736(13)61752-3
11. Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol. 2019;16(11):687-698. doi: 10.1038/s41569-019-0202-5
12. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 1972;287(16):781-787. doi: 10.1056/NEJM197210192871601
13. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi: 10.1002/ejhf.1858
14. Silva D, Gomez-Sanchez MA. Heart Failure: A New Epidemic of Cardiovascular Disease. Acta Med Port. 2016;29(1):10-11. doi: 10.20344/amp.5909
15. Hsu PF, Cheng HM, Sung SH, et al. Hemodynamic Determinants of the Short-Term Blood Pressure Variability: Differential Roles of Arterial Stiffness and Wave Reflection. Am J Hypertens. 2017;30(3):256-263. doi: 10.1093/ajh/hpw144
16. Pencina MJ, Navar AM, Wojdyla D, et al. Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation. 2019;139(13):1603-1611. doi: 10.1161/CIRCULATIONAHA.117.031855
17. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105‐114. doi: 10.1016/0895-4356(88)90084-4
18. Seminog OO, Scarborough P, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute stroke in England: linked national database study of 795 869 adults [published correction appears in BMJ. 2019 Jul 30; 366:4934. BMJ. 2019;365:1778. doi: 10.1136/bmj.l1778
19. Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation. 1997;96(11):3849‐3859. doi: 10.1161/01.cir.96.11.3849
20. Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the interheart study): case-control study. Lancet. 2004;(364):937–952. doi: 10.1016/S0140-6736(04)17018-9
21. O’Donnell M, Xavier D, Liu L, Zhang H, Lim Chin S, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123. doi: 10.1016/S0140-6736(10)60834-3
22. World Health Organization. World Hypertension Day 2019 [Internet]. Geneva; World Health Organization 2020 [citado9 de enero de 2021]. Disponible en: https://www.who.int/news-room/events/world-hypertension-day-2019
23. Liu C, Kraja AT, Smith JA, Brody JA, Franceschini N, Bis JC, et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat Genet. 2016;48(10):1162–70. doi: 10.1038/ng.3660
24. Cooper-DeHoff R, Johnson J. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2015;12(2):110-122. doi: 10.1038/nrneph.2015.176
25. Centers for Disease Control and Prevention (CDC), National Health and Nutrition Examination Survey (NHANES). NHANES 2015-1016 [Internet]. 2016 [citado 09 enero de 2021]. Disponible en: https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/overview.aspx?BeginYear=2015
26. National Heart, Lung and BI (NHLBI). High Blood Pressure [Internet]. 2016 [citadol 09 de enero de 2021.]. Disponible en: https://www.nhlbi.nih.gov/health-topics/high-blood-pressure
27. Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M et al. Heart Disease and Stroke Statistics—2016 Update. Circulation. 2016;133(4):e38-e360. doi: 10.1161/CIR.0000000000000350
28. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2019 Update: A Report from the American Heart Association. Circulation. 2019;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659
29. Park C, Fang J, Hawkins NA, Wang G. Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults. Am J Prev Med. 2017;53(6):S172–S181. doi: 10.1016/j.amepre.2017.07.014
30. Reuter H, Jordan J. Status of hypertension in Europe. Curr Opin Cardiol. 2019;34(4):342-349. doi: 10.1097/HCO.0000000000000642
31. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control : A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441–50. doi: 10.1161/CIRCULATIONAHA.115.018912
32. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan M et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19•1 million participants. Lancet. 2017;389(10064):37-55. doi: 10.1016/S0140-6736(16)31919-5
33. Geldsetzer P, Manne-Goehler J, Marcus M, Ebert C, Zhumadilov Z, Wesseh C et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1•1 million adults. Lancet. 2019;394(10199):652-662. doi: 10.1016/S0140-6736(19)30955-9
34. Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension: a meta-analysis. J Hypertens. 2015;33(2):221–9. doi: 10.1097/HJH.0000000000000428
35. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L et al. Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. New Engl J Med. 2014;371(9):818-827. doi: 10.1056/NEJMoa1311890
36. Chow C, Teo K, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA. 2013;310(9):959-968. doi: 10.1001/jama.2013.184182
37. Yusuf S. Cardiovascular risk and events and country income stratum. N Engl J Med. 2015;372(3):289. doi: 10.1056/NEJMc1412846
38. López-Jaramillo P, Barbosa E, Molina D, Sanchez R, Diaz M, Camacho P et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. J Hypertens. 2019;37(6):1126-1147. doi: 10.1097/HJH.0000000000002072
39. Schargrodsky H, Hernández-Hernández R, Champagne B, Silva H, Vinueza R, Silva Ayçaguer L et al. CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities. Am J Med. 2008;121(1):58-65. doi: 10.1016/j.amjmed.2007.08.038
40. Lanas F, Avezum A, Bautista L, Diaz R, Luna M, Islam S et al. Risk Factors for Acute Myocardial Infarction in Latin America The INTERHEART Latin American Study. Circulation. 2007;115(9):1067-1074. doi: 10.1161/CIRCULATIONAHA.106.633552
41. Lamelas P, Diaz R, Orlandini A, Avezum A, Oliveira G, Mattos A et al. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries. J Hypertens. 2019;37(9):1813-1821. doi: 10.1097/HJH.0000000000002108
42. Anjana RM, Mohan V, Rangarajan S, et al. Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. Diabetes Care. 2020;43(12):3094-3101. doi: 10.2337/dc20-0886
43. Beaney T, Schutte A, Stergiou G, Borghi C, Burger D, Charchar F et al. May Measurement Month 2019 : The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension. 2020;76(2):333-341. doi: 10.1161/HYPERTENSIONAHA.120.14874
44. Barbosa E, Ramirez A, Beaney T, Kobeissi E, Lopez-Jaramillo P, Hernánez-Hernández R et al. May measurement month 2017: Latin America. J Hypertens. 2020;38(6):1183-1188. doi: 10.1097/HJH.0000000000002370
45. Guzman-Tordecilla D, Bernal García A, Rodríguez I. Interventions to increase the pharmacological adherence on arterial hypertension in Latin America: a systematic review. Int J of Public Health. 2019;65(1):55-64. doi: 10.1007/s00038-019-01317-x
46. Camacho P, Gomez-Arbelaez D, Molina D, Sanchez G, Arcos E, Narvaez C et al. Social disparities explain differences in hypertension prevalence, detection and control in Colombia. J Hypertens. 2016;34(12):2344-2352. doi: 10.1097/HJH.0000000000001115
47. Ministerio de Salud y Protección Social. Documento Metodológico Encuesta Nacional de Salud, Bienestar y Envejecimiento SABE Colombia [Internet]. Bogotá: 2021 [citado 09 enero de 2021]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/doc-metodologia-sabe.pdf
48. Barrera L, Gómez F, Ortega D, Corhuelo J, Méndez F. Prevalence, awareness, treatment and control of high blood pressure in the elderly according to the ethnic group. Colombian survey. Colomb Med (Cali). 2019;50(2):115–127. doi: 10.25100/cm.v50i2.4124
49. Hessel P, Rodríguez-Lesmes P, Torres D. Socio-economic inequalities in high blood pressure and additional risk factors for cardiovascular disease among older individuals in Colombia: Results from a nationally representative study. PLOS ONE. 2020;15(6):e0234326. doi: 10.1371/journal.pone.0234326
50. López-Jaramillo P, Otero J, Rueda-Quijano S, Camacho P, Rey J, Sánchez G et al. May Measurement Month 2017: an analysis of blood pressure screening results in Colombia—Americas. Eur Heart J Suppl. 2019;21(Supplement_D):D40-D43. doi: 10.1093/eurheartj/suz087
51. Lopez-Jaramillo P, Otero J, Alvernia J, Ney-Salazar D, Lopez-Lopez J, Accini J et al. May Measurement Month 2018: an analysis of blood pressure screening results from Colombia. Eur Heart J Suppl. 2020;22(Supplement_H):H43-H46. doi: 10.1093/eurheartj/suaa02
52. Otero J, Camacho P, Gómez-Peña L, Rueda-Quijano S, Gómez-Cuellar J, Rey J et al. Medición, control y conocimiento de la presión arterial: Iniciativa Mayo Mes de la Medición Colombia 2017. Hipertensión y Riesgo Vascular. 2020;37(1):4-10. https://doi.org/10.1016/j.hipert.2019.03.004
53. Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo (CAC). Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia 2019 [Internet]. Bogotá D.C. 2020 [citado 09 de enero de 2021]. Disponible en: https://cuentadealtocosto.org/site/wpcontent/uploads/2020/06/CAC.Co_2020_06_24_Libro_Sit_ERC_ 2019V7.pdf
54. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular. Boletín de información técnica especializada de la Cuenta de Alto Costo. Fundación Colombiana del Corazón. 2018;(8):1-8.
55. Manrique-Abril F, Herrera-Amaya G, Manrique-Abril R, Beltrán-Morera J. Costos de un programa de atención primaria en salud para manejo de la hipertensión arterial en Colombia. Revista de Salud Pública. 2018;20(4):465-471. https://doi.org/10.15446/rsap.V20n4.64679
56. Londoño Agudelo E, García Fariñas A, Pérez Ospina V, Taborda Pérez C, Villacrés Landeta T, Battaglioli T et al. Out-of-pocket expenditure for hypertension care: a population-based study in low-income urban Medellin, Colombia. Global Health Action. 2020;13(1):1806527. doi: 10.1080/16549716.2020.1806527
57. Acuña L, Sánchez P, Soler LA, Alvis LF. Enfermedad renal crónica en Colombia: prioridad para la gestión de riesgo. Rev Panam Salud Publica. 2016;40(1):16–22.
58. Yanez N, Useche J, Bayona H, Porras A, Carrasquilla G. Analyses of Mortality and Prevalence of Cerebrovascular Disease in Colombia, South America (2014-2016): A Cross-Sectional and Ecological Study. J Stroke Cerebrovasc Dis. 2020;29(5):104699. doi: 10.1016/j.jstrokecerebrovasdis.2020.104699
59. Guerrero-Pinedo F, Ochoa-Zárate L, Salazar C, Carrillo-Gómez D, Paulo M, Flórez-Elvira L, et al. Association of traditional cardiovascular risk factors in adults younger than 55 years with coronary heart disease. Case-control study. SAGE Open Medicine. 2020;8:205031212093270. doi: 10.1177/2050312120932703
60. Schwalm J, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Lancet. 2019;394(10205):1231-1242. Lancet. 2019;394(10205):1231-1242.
61. Schwalm JR, McCready T, Lamelas P, Musa H, Lopez-Jaramillo P, Yusoff K, McKee M, Camacho PA, Lopez-Lopez J, Majid F, Thabane L, Islam S, Yusuf S. Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study. Am Heart J. 2018; 203:57-66. doi: 10.1016/j.ahj.2018.06.004